Literature DB >> 21102609

MET signalling: principles and functions in development, organ regeneration and cancer.

Livio Trusolino1, Andrea Bertotti, Paolo M Comoglio.   

Abstract

The MET tyrosine kinase receptor (also known as the HGF receptor) promotes tissue remodelling, which underlies developmental morphogenesis, wound repair, organ homeostasis and cancer metastasis, by integrating growth, survival and migration cues in response to environmental stimuli or cell-autonomous perturbations. The versatility of MET-mediated biological responses is sustained by qualitative and quantitative signal modulation. Qualitative mechanisms include the engagement of dedicated signal transducers and the subcellular compartmentalization of MET signalling pathways, whereas quantitative regulation involves MET partnering with adaptor amplifiers or being degraded through the shedding of its extracellular domain or through intracellular ubiquitylation. Controlled activation of MET signalling can be exploited in regenerative medicine, whereas MET inhibition might slow down tumour progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21102609     DOI: 10.1038/nrm3012

Source DB:  PubMed          Journal:  Nat Rev Mol Cell Biol        ISSN: 1471-0072            Impact factor:   94.444


  168 in total

Review 1.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis.

Authors:  Shinya Mizuno; Kunio Matsumoto; Ming-Yue Li; Toshikazu Nakamura
Journal:  FASEB J       Date:  2005-01-21       Impact factor: 5.191

3.  Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor.

Authors:  K Nabeshima; T Inoue; Y Shimao; Y Okada; Y Itoh; M Seiki; M Koono
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

4.  MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2).

Authors:  Seonhoe Kim; Ui Jin Lee; Mi Na Kim; Eun-Ju Lee; Ji Young Kim; Mi Young Lee; Sorim Choung; Young Joo Kim; Young-Chul Choi
Journal:  J Biol Chem       Date:  2008-05-02       Impact factor: 5.157

5.  Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA.

Authors:  W M Mars; R Zarnegar; G K Michalopoulos
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

6.  Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor.

Authors:  Y Uehara; O Minowa; C Mori; K Shiota; J Kuno; T Noda; N Kitamura
Journal:  Nature       Date:  1995-02-23       Impact factor: 49.962

7.  CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.

Authors:  Patrick A Singleton; Ravi Salgia; Liliana Moreno-Vinasco; Jaideep Moitra; Saad Sammani; Tamara Mirzapoiazova; Joe G N Garcia
Journal:  J Biol Chem       Date:  2007-08-16       Impact factor: 5.157

8.  Sema4D induces angiogenesis through Met recruitment by Plexin B1.

Authors:  Paolo Conrotto; Donatella Valdembri; Simona Corso; Guido Serini; Luca Tamagnone; Paolo Maria Comoglio; Federico Bussolino; Silvia Giordano
Journal:  Blood       Date:  2005-01-04       Impact factor: 22.113

9.  Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase.

Authors:  D Nath; N J Williamson; R Jarvis; G Murphy
Journal:  J Cell Sci       Date:  2001-03       Impact factor: 5.285

10.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

Authors:  L Naldini; K M Weidner; E Vigna; G Gaudino; A Bardelli; C Ponzetto; R P Narsimhan; G Hartmann; R Zarnegar; G K Michalopoulos
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more
  448 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

2.  MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.

Authors:  Chang-Il Hwang; Jinhyang Choi; Zongxiang Zhou; Andrea Flesken-Nikitin; Alexander Tarakhovsky; Alexander Yu Nikitin
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

3.  Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.

Authors:  Sung Keun Jung; Mee-Hyun Lee; Do Young Lim; Jong Eun Kim; Puja Singh; Sung-Young Lee; Chul-Ho Jeong; Tae-Gyu Lim; Hanyong Chen; Young-In Chi; Joydeb Kumar Kundu; Nam Hyouck Lee; Charles C Lee; Yong-Yeon Cho; Ann M Bode; Ki Won Lee; Zigang Dong
Journal:  J Biol Chem       Date:  2014-11-03       Impact factor: 5.157

4.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

5.  Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.

Authors:  Justin M M Cates; Jennifer O Black; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Cheryl M Coffin
Journal:  Hum Pathol       Date:  2012-04-18       Impact factor: 3.466

6.  Cross-analysis of gene and miRNA genome-wide expression profiles in human fibroblasts at different stages of transformation.

Authors:  Paola Ostano; Silvia Bione; Cristina Belgiovine; Ilaria Chiodi; Chiara Ghimenti; A Ivana Scovassi; Giovanna Chiorino; Chiara Mondello
Journal:  OMICS       Date:  2012 Jan-Feb

7.  Combined Systemic Disruption of MET and Epidermal Growth Factor Receptor Signaling Causes Liver Failure in Normal Mice.

Authors:  Anastasia Tsagianni; Wendy M Mars; Bharat Bhushan; William C Bowen; Anne Orr; John Stoops; Shirish Paranjpe; George C Tseng; Silvia Liu; George K Michalopoulos
Journal:  Am J Pathol       Date:  2018-07-20       Impact factor: 4.307

8.  Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.

Authors:  Liping Huang; Yifei Qin; Qiang Zuo; Kavita Bhatnagar; Jingbo Xiong; Glenn Merlino; Yanlin Yu
Journal:  Int J Cancer       Date:  2017-12-15       Impact factor: 7.396

9.  Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.

Authors:  Ying Zhang; Kaitlyn E Farenholtz; Yanzhi Yang; Fadila Guessous; Charles G Dipierro; Valerie S Calvert; Jianghong Deng; David Schiff; Wenjun Xin; Jae K Lee; Benjamin Purow; James Christensen; Emanuel Petricoin; Roger Abounader
Journal:  Clin Cancer Res       Date:  2013-02-05       Impact factor: 12.531

10.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.